Search research articles
Contact Us
Filters
Showing results (111-120 of 127) with videos related to
Page
of 13
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 22, 2025
Phased Variant-Supported Circulating Tumor DNA as a Prognostic Biomarker After First-Line Treatment in Large B-Cell Lymphoma: Findings From the DIRECT Study
Joanna A Krupka, Ilias Moutsopoulos, Natasha H Cutmore, et al.
The New England Journal of Medicine
|
June 16, 2025
Measurable Residual Disease-Guided Therapy for Chronic Lymphocytic Leukemia
Talha Munir, Sean Girvan, David A Cairns, et al.
Blood Advances
|
January 12, 2022
Results of a United Kingdom real-world study of polatuzumab vedotin, bendamustine, and rituximab for relapsed/refractory DLBCL
Michael Northend, William Wilson, Wendy Osborne, et al.
Haematologica
|
February 22, 2020
Comparative analysis of targeted novel therapies in relapsed, refractory chronic lymphocytic leukaemia
Toby A Eyre, Nicole Lamanna, Lindsey E Roeker, et al.
The Lancet. Haematology
|
January 29, 2021
MATRix-RICE therapy and autologous haematopoietic stem-cell transplantation in diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA): an international, single-arm, phase 2 trial
Andrés J M Ferreri, Jeanette K Doorduijn, Alessandro Re, et al.
The Lancet. Haematology
|
May 3, 2016
Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial
Andrés J M Ferreri, Kate Cwynarski, Elisa Pulczynski, et al.
Nature Cancer
|
March 25, 2022
Immune responses against SARS-CoV-2 variants after two and three doses of vaccine in B-cell malignancies: UK PROSECO study
Sean H Lim, Beth Stuart, Debora Joseph-Pietras, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 11, 2026
High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Multicenter Analysis
Matthew R Wilson, Katharine L Lewis, Amy A Kirkwood, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 21, 2019
Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice
Lindsey E Roeker, Christopher P Fox, Toby A Eyre, et al.
Blood
|
October 13, 2023
The influence of immunodeficiency, disease features, and patient characteristics on survival in plasmablastic lymphoma
Pietro R Di Ciaccio, Mark N Polizzotto, Kate Cwynarski, et al.
Page
of 13
Search research articles
Search
Showing results (111-120 of 127) with videos related to
Sort By:
Page
of 13
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 22, 2025
Phased Variant-Supported Circulating Tumor DNA as a Prognostic Biomarker After First-Line Treatment in Large B-Cell Lymphoma: Findings From the DIRECT Study
Joanna A Krupka, Ilias Moutsopoulos, Natasha H Cutmore, et al.
The New England Journal of Medicine
|
June 16, 2025
Measurable Residual Disease-Guided Therapy for Chronic Lymphocytic Leukemia
Talha Munir, Sean Girvan, David A Cairns, et al.
Blood Advances
|
January 12, 2022
Results of a United Kingdom real-world study of polatuzumab vedotin, bendamustine, and rituximab for relapsed/refractory DLBCL
Michael Northend, William Wilson, Wendy Osborne, et al.
Haematologica
|
February 22, 2020
Comparative analysis of targeted novel therapies in relapsed, refractory chronic lymphocytic leukaemia
Toby A Eyre, Nicole Lamanna, Lindsey E Roeker, et al.
The Lancet. Haematology
|
January 29, 2021
MATRix-RICE therapy and autologous haematopoietic stem-cell transplantation in diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA): an international, single-arm, phase 2 trial
Andrés J M Ferreri, Jeanette K Doorduijn, Alessandro Re, et al.
The Lancet. Haematology
|
May 3, 2016
Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial
Andrés J M Ferreri, Kate Cwynarski, Elisa Pulczynski, et al.
Nature Cancer
|
March 25, 2022
Immune responses against SARS-CoV-2 variants after two and three doses of vaccine in B-cell malignancies: UK PROSECO study
Sean H Lim, Beth Stuart, Debora Joseph-Pietras, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 11, 2026
High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Multicenter Analysis
Matthew R Wilson, Katharine L Lewis, Amy A Kirkwood, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 21, 2019
Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice
Lindsey E Roeker, Christopher P Fox, Toby A Eyre, et al.
Blood
|
October 13, 2023
The influence of immunodeficiency, disease features, and patient characteristics on survival in plasmablastic lymphoma
Pietro R Di Ciaccio, Mark N Polizzotto, Kate Cwynarski, et al.
Page
of 13